Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage biotechnology company pioneering drug discovery through its Dynamo™ platform, which analyzes protein motion to develop precision therapies for oncology and genetic diseases. This page provides real-time access to official company announcements, research breakthroughs, and strategic developments.
Investors and industry professionals will find curated updates including clinical trial progress, regulatory milestones, and partnership announcements. All content is sourced directly from Relay Therapeutics’ communications and verified financial disclosures, ensuring reliability for decision-making.
Key coverage areas include innovations in small molecule therapeutics, updates on the Dynamo platform’s applications, and analyses of Relay’s position within the precision medicine landscape. Content is organized chronologically for easy tracking of the company’s evolution.
Bookmark this page to monitor Relay Therapeutics’ advancements in targeting historically undruggable proteins. For comprehensive insights into RLAY’s scientific and corporate developments, revisit regularly or subscribe to Stock Titan’s update alerts.
Relay Therapeutics, a clinical-stage precision medicine company (Nasdaq: RLAY), will participate in two upcoming investor conferences. The management will join the TD Cowen 5th Annual Oncology Innovation Summit virtually on May 28, 2024, at 9:30 a.m. ET and the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 8:40 a.m. ET. Both events will be webcast live and accessible through Relay Therapeutics' website, with replays available for 30 days.
Relay Therapeutics, Inc. (Nasdaq: RLAY) will host a New Program and Platform event on June 6, 2024, to disclose new programs from its existing pre-clinical pipeline and showcase how the Dynamo™ platform contributed to these discoveries. The event will offer in-person attendance to select investors and a virtual webcast for all interested parties.
Relay Therapeutics, Inc. reported first quarter 2024 financial results with $750 million in cash, cash equivalents, and investments, funding operations into the second half of 2026. The company highlighted progress in RLY-2608 development program, enrollment in RLY-2608 doublet and triplet studies, and anticipation of data updates for RLY-2608 and Lirafugratinib in the second half of 2024. Financially, revenue increased to $10.0 million, R&D expenses decreased, G&A expenses increased slightly, and net loss improved compared to the first quarter of 2023.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
